BALA CYNWYD, Pa., July 14, 2026 (GLOBE NEWSWIRE) — Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com<\/a>) or Marc Ackerman (mackerman@brodskysmith.com<\/a>) at 855-576-4847. There is no cost or financial obligation to you.<\/p>\n TriCo Bancshares (Nasdaq \u2013 TCBK)<\/strong><\/p>\n Under the terms of the Merger Agreement, TriCo Bancshares will be acquired by First Hawaiian, Inc. (Nasdaq – FHB) in an all-stock transaction where TriCo\u2019s shareholders will receive 2.095 First Hawaiian shares for each TriCo share, representing $63.12 per share as of First Hawaiian\u2019s closing stock price on July 10, 2026. Upon closing of the transaction, First Hawaiian and TriCo shareholders are expected to own approximately 65% and 35%, respectively, of the combined company. The investigation concerns whether the TriCo Bancshares Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.<\/p>\n Additional information can be found at https:\/\/www.brodskysmith.com\/cases\/trico-bancshares-nasdaq-tcbk\/<\/a>.<\/p>\n Twin Vee PowerCats Co. (Nasdaq -VEEE)<\/strong><\/p>\n Under the terms of the Merger Agreement, Twin Vee will be acquired by USFM Corporation. Twin Vee\u2019s recreational marine business will be separated before closing into a private trust owned economically by Twin Vee\u2019s existing shareholders through contingent value rights (CVRs). Before the merger closes, the Company\u2019s marine business will be transferred to a newly created private trust. Shareholders will receive contingent value rights (CVRs) from the operations of that marine business. Shareholders will also receive shares of the combined public company following the merger with USFM Corporation\u2019s subsidiary. The investigation concerns whether the Twin Vee Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.<\/p>\n Additional information can be found at https:\/\/www.brodskysmith.com\/cases\/twin-vee-powercats-co-nasdaq-veee\/<\/a>.<\/p>\n Crinetics Pharmaceuticals, Inc. (Nasdaq \u2013 CRNX)<\/strong><\/p>\n Under the terms of the Merger Agreement, Crinetics Pharmaceuticals will be acquired by Vertex Pharmaceuticals Incorporated (Nasdaq – VRTX) for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The investigation concerns whether the Crinetics Pharmaceuticals Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.<\/p>\n
![\"\"](\"https:\/\/ml.globenewswire.com\/media\/ZWRkODI1NzUtNGNhNS00ZGE3LTliOTItY2E4ODQwYmZlMjBiLTExOTk4MzEtMjAyNi0wNy0xNC1lbg==\/tiny\/Brodsky-Smith-LLC.png\")
\n <\/div>\n","protected":false},"excerpt":{"rendered":"